Skip to main content
Kolinpharma logo

Kolinpharma — Investor Relations & Filings

Ticker · KIP ISIN · IT0005322950 LEI · 815600FC8F1A3BED2743 XMIL Manufacturing
Open in API
Filings indexed 222 across all filing types
Latest filing 2021-06-18 Regulatory Filings
Country IT Italy
Listing XMIL KIP

About Kolinpharma

https://www.kolinpharma.com/index-en

Kolinpharma is a nutraceutical company established in 2013, specializing in the research and development of innovative products designed to improve well-being and quality of life. The company's core activities are centered on scientific research and product innovation, creating high-quality nutraceuticals. It operates an in-house R&D department and collaborates with leading universities for in-vitro and clinical studies. As a certified B Corporation, Kolinpharma adheres to high standards of social and environmental performance. The company distributes its proprietary branded products through a qualified network of medical-scientific representatives.

Recent filings

Filing Released Lang Actions
KOLINPHARMA, LANCIA DOLTENDIX®, IL NUOVO INTEGRATORE CERTIFICATO E PATENT PENDING
Regulatory Filings Classification · 1% confidence The document is a formal communication from KOLINPHARMA S.p.A. dated June 18, 2021, identified as 'Informazione Regolamentata' (Regulated Information) on the AIM-Italia market. The subject is the launch of a new product, DOLTENDIX®. This type of announcement, detailing a significant business event (product launch) that is not a standard periodic financial report (like 10-K or IR), nor a management change (MANG), nor a capital event (CAP/SHA), nor a dividend notice (DIV), typically falls under general regulatory announcements. Since it is a specific, non-periodic corporate action announcement, and it is not a transcript (CT), proxy material (PSI), or director dealing (DIRS), the most appropriate general category for a significant, non-standard corporate update on the Italian market is 'Regulatory Filings' (RNS), which serves as a fallback for miscellaneous regulatory announcements that don't fit the highly specific categories. The document length is substantial (6902 chars), so it is the announcement itself, not just a notice of publication (RPA).
2021-06-18 Italian
KOLINPHARMA, SOTTOSCRITTO CONTRATTO IN ESCLUSIVA PER L'ITALIA PER IL DOLATROX HCC
Regulatory Filings Classification · 1% confidence The document is a formal communication from KOLINPHARMA S.p.A. dated June 16, 2021, identified by the header 'Informazione Regolamentata' (Regulated Information) and the object 'KOLINPHARMA, SOTTOSCRITTO CONTRATTO IN ESCLUSIVA PER L'ITALIA PER IL DOLATROX HCC'. The content details the signing of an exclusive distribution contract for a medical device. This type of announcement, which communicates a significant business event or agreement that is not a standard periodic financial report (like 10-K or IR) or a specific insider trade/dividend notice, falls under general regulatory announcements. Since it is a specific business update that doesn't fit the other specialized categories (like M&A, Capital Change, or Earnings Release), the most appropriate classification is the general regulatory filing category, RNS (Regulatory Filings), which serves as a fallback for miscellaneous regulatory announcements.
2021-06-16 Italian
KOLINPHARMA, 1Q 2021 IN SIGNIFICATIVA CRESCITA LE PRESCRIZIONI MEDICHE
Earnings Release Classification · 1% confidence The document is an official communication (Informazione Regolamentata) from KOLINPHARMA S.p.A. dated May 20, 2021. The subject line ('Oggetto') explicitly states 'KOLINPHARMA, 1Q 2021 IN SIGNIFICATIVA CRESCITA LE PRESCRIZIONI MEDICHE' (KOLINPHARMA, 1Q 2021 Significant Growth in Medical Prescriptions). The text details key performance indicators (KPIs) for the first quarter (1Q 2021) regarding medical prescriptions, comparing them to 1Q 2020 and 1Q 2019. This content—a summary of operational and financial highlights for a specific interim period (Q1)—is characteristic of an Earnings Release (ER). Although it mentions KPIs approved by the Board, it is the initial announcement of results, not a comprehensive report (like an IR or 10-K). It is not a transcript (CT), a full presentation (IP), or a notice of a future report publication (RPA). Therefore, it is classified as an Earnings Release. Q1 2021
2021-05-20 Italian
KOLINPHARMA PARTECIPA ALL' AIM RETAIL INVESTOR DAY
Report Publication Announcement Classification · 1% confidence The document is an official regulatory announcement (Informazione Regolamentata) dated May 13, 2021, concerning KOLINPHARMA S.p.A. The subject ('Oggetto') is 'RETAIL INVESTOR DAY'. The text explicitly states that the company will participate in the 'AIM RETAIL INVESTOR DAY' on May 19, 2021, where the President will illustrate the company's strategic development. This is an announcement about an upcoming investor event, not the presentation itself, the transcript, or a formal financial report (like 10-K or IR). Since it is an announcement regarding an investor relations activity, it fits best under Investor Presentation (IP) if the presentation material is the focus, or potentially a Regulatory Filing (RNS) if it's a general disclosure. However, given the specific nature of announcing participation in an investor day where strategy will be presented, and the document mentions the presentation will be made available later, it strongly suggests the core purpose is related to investor communication about future strategy/performance, which aligns closely with Investor Presentation (IP) materials being announced, or a general announcement about an investor event. Since the document itself is an announcement of participation in an event where an investor presentation will occur, and it is a formal regulatory disclosure, it is most accurately classified as an announcement of an investor relations activity. Given the options, 'Investor Presentation' (IP) is the closest category for the *subject matter* being announced, but because this is a short announcement *about* the event rather than the presentation itself, and it is a formal regulatory disclosure, 'Regulatory Filings' (RNS) is a strong candidate as a fallback for specific event announcements. Looking closely at the content: it announces participation in an 'Investor Day' where the strategy will be illustrated. This is a precursor to an Investor Presentation (IP). However, the document itself is a formal regulatory notice (REGEM) announcing participation in a roadshow. If the document were the actual presentation slides, it would be IP. Since it is the announcement of participation, and it's a formal disclosure, RNS is the safest general regulatory classification, but IP captures the intent better if we consider the substance being promoted. Given the context of announcing participation in an investor event where strategy is presented, and the document is short and regulatory, I will lean towards the category that best describes the *type* of information being disseminated to investors, which is related to an Investor Presentation (IP). However, since the document is a formal regulatory notice about an upcoming event, and not the presentation itself, RNS (Regulatory Filings) is the most appropriate catch-all for formal announcements that don't fit the specific report types. Let's re-evaluate: The document is a formal regulatory disclosure (REGEM) announcing participation in an Investor Day. This is a standard type of disclosure. It is not a 10-K, AR, ER, or IR. It is not a DIV or DIRS. It is an announcement about an investor event. This type of announcement often falls under RNS if no other specific category fits perfectly. Since 'Investor Presentation' (IP) is for the presentation itself, and this is the announcement of attendance, RNS is the most robust classification for a general regulatory announcement about an upcoming investor engagement event. I will use RNS as the fallback for this specific type of regulatory announcement about an event.
2021-05-13 Italian
KOLINPHARMA - L'ASSEMBLEA APPROVA IL BILANCIO 2020, IL PIANO DI ACQUISTO E DISPOSIZIONE AZIONI PROPRIE E ASSUME QUALIFICA DI SOCIETA' BENEFIT
AGM Information Classification · 1% confidence The document is a press release dated April 29, 2021, detailing the resolutions passed at the Ordinary and Extraordinary Shareholders' Meeting of KOLINPHARMA S.p.A. The key approvals include the 2020 Financial Statements (Bilancio 2020), authorization for share buybacks/disposals, and the adoption of the 'Società Benefit' (Benefit Corporation) status. The text explicitly mentions key financial results (Revenues, EBITDA, Net Income) and the presentation of the 2020 Sustainability Report. Since the document summarizes the outcomes of the General Meeting and includes resolutions on capital structure (share buyback), it strongly relates to shareholder decisions and the AGM. The title itself mentions 'L'ASSEMBLEA APPROVA...' (The Assembly Approves...). While it contains financial results (ER/IR elements) and sustainability info (SR elements), the primary context is the formal meeting's outcome. The most fitting category for materials presented or decided upon at the Annual General Meeting is AGM-R (AGM Information). It is not a simple Earnings Release (ER) as it covers multiple corporate governance and capital structure decisions, nor is it just a standard Interim Report (IR) or Annual Report (10-K).
2021-04-29 Italian
KOLINPHARMA,integrazione calendario finanziario, partecipa Smart Green Investor day e Aim Italia Conference 2021
Report Publication Announcement Classification · 1% confidence The document is a formal communication from KOLINPHARMA S.p.A. dated April 9, 2021, identified as 'Informazione Regolamentata' (Regulated Information). The subject ('Oggetto') is 'day e Aim Italia Conference 2021' and the text announces the company's participation in two upcoming investor events: the 'SMART GREEN INVESTOR DAY' on April 14, 2021, and the 'AIM ITALIA CONFERENCE 2021' on May 26, 2021. It also includes an updated financial calendar listing future board meetings and shareholder assembly dates. This document is not a full financial report (10-K or IR), nor is it a transcript (CT) or a specific results release (ER). It is an announcement detailing the company's schedule for engaging with investors and updating the market on future corporate events and presentations. This fits best under the category of a general regulatory announcement or an announcement regarding investor relations activities, which aligns closely with 'Report Publication Announcement' (RPA) if it were announcing a report, or 'Regulatory Filings' (RNS) as a general announcement. Since it is specifically updating the market on participation in investor conferences and providing an updated financial calendar, it is a form of corporate communication that updates the market on future investor-facing events. Given the options, 'RPA' is used for announcing the publication of reports, and this announces participation in conferences. 'RNS' is the general regulatory fallback. However, because it details participation in investor events and updates the financial calendar, it is a specific type of corporate disclosure. Given the context of investor engagement updates, and lacking a specific 'Investor Event Announcement' code, 'RNS' (Regulatory Filings/General Regulatory Announcements) is the most appropriate fallback for this type of market update that isn't a core financial report or a specific management/dividend announcement.
2021-04-09 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.